KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $79.3 million.

  • Royalty Pharma's Other Non-Current Assets rose 13645.55% to $79.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $79.3 million, marking a year-over-year increase of 13645.55%. This contributed to the annual value of $79.3 million for FY2025, which is 13645.55% up from last year.
  • Royalty Pharma's Other Non-Current Assets amounted to $79.3 million in Q4 2025, which was up 13645.55% from $86.6 million recorded in Q3 2025.
  • Royalty Pharma's 5-year Other Non-Current Assets high stood at $86.6 million for Q3 2025, and its period low was $3.9 million during Q1 2022.
  • Moreover, its 5-year median value for Other Non-Current Assets was $28.7 million (2023), whereas its average is $29.9 million.
  • Per our database at Business Quant, Royalty Pharma's Other Non-Current Assets plummeted by 8398.86% in 2024 and then soared by 71789.22% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Other Non-Current Assets stood at $4.1 million in 2021, then skyrocketed by 614.81% to $29.6 million in 2022, then tumbled by 77.99% to $6.5 million in 2023, then soared by 414.17% to $33.5 million in 2024, then soared by 136.46% to $79.3 million in 2025.
  • Its last three reported values are $79.3 million in Q4 2025, $86.6 million for Q3 2025, and $85.5 million during Q2 2025.